Recent studies have reported that CCL2 is overexpressed in a majority of solid cancer types, including breast cancer, prostate cancer, esophageal carcinoma, colon cancer, pancreatic cancer, ovarian cancer [8, 13–17] and NSCLC [18]. This evidence concerns the gene CCL2 and non-small cell lung carcinoma.